Research programme: immunostimulating gene therapy - Multimeric Biotherapeutics
Latest Information Update: 01 Nov 2011
At a glance
- Originator Multimeric Biotherapeutics
- Class Gene therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Oct 2011 Preclinical development is ongoing